Moreover, we found that GDYO had no toxic effect on normal hematopoietic cells and other non-immune organs, suggesting the therapeutic potential of GDYO to treat DNMT3A-mutant AML patients in the future. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.